​

PTC Therapeutics (PTCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PTCT Stock Forecast

PTC Therapeutics (PTCT) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $55.00, with a high of $58.00 and a low of $52.00. This represents a 18.51% increase from the last price of $46.41.

$25 $32 $39 $46 $53 $60 High: $58 Avg: $55 Low: $52 Last Closed Price: $46.41

PTCT Stock Rating

PTC Therapeutics stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (60.87%), 7 Hold (30.43%), 2 Sell (8.70%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 2 7 14 Strong Sell Sell Hold Buy Strong Buy

PTCT Price Target Upside V Benchmarks

TypeNameUpside
StockPTC Therapeutics18.51%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$42.75
Last Closing Price$46.41$46.41$46.41
Upside/Downside---7.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 253641115
Mar, 253631215
Feb, 253631215
Jan, 253631215
Dec, 243661218
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 07, 2025Brian AbrahamsRBC Capital$58.00$44.6130.02%24.97%
Nov 27, 2024Joel BeattyRobert W. Baird$52.00$45.0915.32%12.04%
Oct 11, 2024Jeffrey HungMorgan Stanley$45.00$38.4816.94%-3.04%
Aug 26, 2024Colin BristowUBS$47.00$34.9934.32%1.27%
Jul 12, 2024Jeffrey HungMorgan Stanley$32.00$33.20-3.61%-31.05%
May 20, 2024Paul ChoiGoldman Sachs$32.00$40.12-20.24%-31.05%
May 20, 2024Kelly ShiJefferies$46.00$39.8115.55%-0.88%
Apr 26, 2024Jeffrey HungMorgan Stanley$30.00$28.575.01%-35.36%
Dec 14, 2022Goldman Sachs$35.00$38.94-10.12%-24.59%
Jun 23, 2022Brian AbrahamsRBC Capital$46.00$38.2920.14%-0.88%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025ScotiabankSector Performinitialise
Feb 03, 2025Cantor FitzgeraldOverweightOverweighthold
Jan 29, 2025Cowen & Co.HoldHoldhold
Jan 07, 2025RBC CapitalOutperformOutperformhold
Oct 11, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Sep 05, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Sep 05, 2024Cowen & Co.HoldHoldhold
Aug 26, 2024UBSBuyupgrade
Aug 09, 2024Cowen & Co.HoldHoldhold
Aug 09, 2024BarclaysEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.64$-7.43$-7.79$-8.37$-4.73----
Avg Forecast$-6.32$-6.68$-6.96$-7.09$-4.52$-1.40$-1.63$-0.53$0.32
High Forecast$-5.18$-5.48$-4.15$-5.97$-3.20$-0.57$1.00$1.54$0.62
Low Forecast$-7.30$-7.72$-14.90$-9.02$-5.17$-2.36$-6.27$-3.09$0.22
Surprise %5.06%11.23%11.93%18.05%4.65%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$380.77M$538.59M$698.80M$937.82M$806.78M----
Avg Forecast$376.02M$524.98M$716.43M$943.98M$797.55M$726.66M$884.80M$1.09B$1.16B
High Forecast$421.08M$587.90M$1.35B$945.10M$797.70M$778.11M$897.16M$1.12B$1.98B
Low Forecast$323.93M$452.26M$494.03M$942.01M$797.40M$675.21M$872.44M$1.05B$879.21M
Surprise %1.26%2.59%-2.46%-0.65%1.16%----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-438.16M$-523.90M$-559.02M$-626.60M$-363.30M----
Avg Forecast$-1.21B$-436.99M$-398.38M$-626.60M$-313.22M$-46.36M$-145.50M$-63.54M$23.91M
High Forecast$-971.32M$-349.59M$-318.70M$-501.28M$-239.54M$-42.57M$74.52M$115.61M$46.13M
Low Forecast$-1.46B$-524.39M$-478.05M$-751.92M$-386.90M$-176.78M$-469.44M$-231.58M$16.44M
Surprise %-63.91%19.89%40.32%-15.99%----

PTCT Forecast FAQ

Is PTC Therapeutics stock a buy?

PTC Therapeutics stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 7 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that PTC Therapeutics is a favorable investment for most analysts.

What is PTC Therapeutics's price target?

PTC Therapeutics's price target, set by 23 Wall Street analysts, averages $55 over the next 12 months. The price target range spans from $52 at the low end to $58 at the high end, suggesting a potential 18.51% change from the previous closing price of $46.41.

How does PTC Therapeutics stock forecast compare to its benchmarks?

PTC Therapeutics's stock forecast shows a 18.51% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for PTC Therapeutics over the past three months?

  • April 2025: 20.00% Strong Buy, 40.00% Buy, 26.67% Hold, 6.67% Sell, 6.67% Strong Sell.
  • March 2025: 20.00% Strong Buy, 40.00% Buy, 20.00% Hold, 6.67% Sell, 13.33% Strong Sell.
  • February 2025: 20.00% Strong Buy, 40.00% Buy, 20.00% Hold, 6.67% Sell, 13.33% Strong Sell.

What is PTC Therapeutics’s EPS forecast?

PTC Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.4, marking a -70.40% decrease from the reported $-4.73 in 2024. Estimates for the following years are $-1.63 in 2026, $-0.53 in 2027, and $0.32 in 2028.

What is PTC Therapeutics’s revenue forecast?

PTC Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $726.66M, reflecting a -9.93% decrease from the reported $806.78M in 2024. The forecast for 2026 is $884.8M, followed by $1.09B for 2027, and $1.16B for 2028.

What is PTC Therapeutics’s net income forecast?

PTC Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-46.358M, representing a -87.24% decrease from the reported $-363M in 2024. Projections indicate $-145M in 2026, $-63.541M in 2027, and $23.91M in 2028.